Revenue Breakdown
Composition ()
No data
Revenue Streams
Ascendis Pharma A/S (ASND) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial sale of products, accounting for 90.7% of total sales, equivalent to €193.79M. Other significant revenue streams include Milestones and Rendering of services. Understanding this composition is critical for investors evaluating how ASND navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Ascendis Pharma A/S maintains a gross margin of 90.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 4.00%, while the net margin is -13.56%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ASND converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ASND competes directly with industry leaders such as IONS and RGC. With a market capitalization of $15.00B, it holds a leading position in the sector. When comparing efficiency, ASND's gross margin of 90.47% stands against IONS's 96.09% and RGC's N/A. Such benchmarking helps identify whether Ascendis Pharma A/S is trading at a premium or discount relative to its financial performance.
